According to 2017 guidelines on molecular biomarker testing for the evaluation of CRC from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology, tissues from metastatic or recurrent CRC are the preferred specimens for treatment-predictive biomarker testing. In their absence, primary tumor tissue is an acceptable alternative.
Formalin-fixed, paraffin-embedded tissue is an acceptable specimen for molecular biomarker mutational testing in CRC. The use of cytology specimens requires additional adequate validation, as would any changes in tissue-processing protocols.
Learn more about guidelines for biomarker testing in CRC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Ali Alqahtani. Fast Five Quiz: Precision Medicine and Genetic Testing for Colorectal Cancer - Medscape - Jun 17, 2022.